Pune's Mylab Discovery Solutions' CoviSelf, which gives results in 15 minutes, gets ICMR nod
From helping their employees infected with the Covid-19 virus to vaccinating them or supporting the families of those who might have succumbed to the infection, several companies in India are trying to do their bit in this difficult time. Some have even widened their support net to include all stakeholders as well as an extended community. To the families of the employees it lost to Covid-19, Noida-headquartered IT services and consulting company HCL Technologies is, for instance, paying salary for a year, medical insurance for three years and extending support for their children's education for five years.
However, Cipla was very clear it does not want to get into vaccine manufacturing.
Thirteen companies have joined the Rs 1-trillion-plus market capitalisation club this year, so far. This even as the benchmark Sensex has gained less than 3 per cent on a year-to-date basis, underscoring the bullish undercurrent in the broader market. The trend shows a harsh second wave of Covid-19, subsequent lockdowns, and hit to the economic activity has made little dent into India Inc or shareholders' wealth. At the start of the year, there were 29 companies with a market value of more than Rs 1 trillion.
This apart, to further increase capacities, Bharat Biotech has partnered with Indian Immunologicals (IIL) to manufacture the drug substance for Covaxin. The technology transfer process is underway and IIL has the 'capabilities and expertise' to manufacture the inactivated viral vaccines at commercial scale.
India expects 2.16 billion doses of Covid-19 vaccines between August and December, including the jabs that are currently in clinical trials, reports Sohini Das
Apollo Hospitals and Fortis Healthcare are open to importing vaccines.
Although the number of resignations came down at Cognizant in April and continued to slow in May, the impact of attrition would play out in the second quarter also because of the longer notice period in India.
The API of Paracetamol, a fever and pain medication, has grown 25 per cent from Rs 450-480 per kg in December 2020 to Rs 580-600 per kg in April. When compared to the pre-Covid prices of December 2019, the surge is much steeper -- around 140 per cent, reports Sohini Das.
Drugs that are used to treat Covid or used by people as immunity boosters have seen a jump in sales and, in turn, rankings.
While there is a shortage of testing kits, manpower and capacities, India does not have other scalable testing options.
'This government did not have any plan for safety stocks of essential medicines.'
When compared to the domestic sales of April 2019, the growth is around 37 per cent. However, compared to the previous month (March), the growth is 18.4 per cent.
Artificial shortages and brazen hawking of the drug on the streets at 15 times the normal price rule the day as the official machinery tries desperately to stamp out the parallel market, reports Sohini Das
Delhi, which has been one of the worst affected states, accounted for less than two per cent of total vaccinations in the 18-44 age-group.
In 2020-21, Indian firms offered to buy back shares worth Rs 39,295 crore, or 97% more than Rs 19,972 cr proposed in the previous financial year.
Covid-19, US yields, dollar to weigh on equity flows in the near term.
Initial data has shown immunity triggered by the two mRNA vaccines -- Pfizer-BioNTech and Moderna -- lasts for at least six months
The 30-share bluechip index is rebalanced on a semi-annual basis with next rejig slated for June 18.
To be able to manage any such uptick, Indian IT services players are hiring more locals, and relying on hybrid work models.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances